Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
| Autor: | Hua Qian, Haibin Chen, Sheena Patel, Jinping Li, Dimple Patel, Shi-Wen Jiang, John R Curcuru, Taylor O Johns |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Poor prognosis Cell Survival Clinical Biochemistry Elevated serum 03 medical and health sciences WAP Four-Disulfide Core Domain Protein 2 0302 clinical medicine Internal medicine Drug Discovery Biomarkers Tumor Animals Humans Medicine Viability assay Cell Proliferation Ovarian Neoplasms Pharmacology business.industry Cell growth Endometrial cancer Proteins Prognosis medicine.disease Endometrial Neoplasms 030104 developmental biology Drug Resistance Neoplasm Apoptosis 030220 oncology & carcinogenesis Cancer cell Molecular Medicine Biomarker (medicine) Female Neoplasm Recurrence Local business |
| Zdroj: | Current Drug Targets. 18 |
| ISSN: | 1389-4501 |
| DOI: | 10.2174/1389450118666170404154929 |
| Popis: | Background HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers' poor prognosis. Objective This literature review investigates the relationship between serum HE4 levels and the recurrence of ovarian and endometrial cancer. Conclusion HE4 displays malignant behavior by promoting cancer cells to skip from G1 phase to S phase, maintaining cell viability, encouraging cell proliferation, inhibiting cell apoptosis, and increasing resistance to drug treatments. Further studies are required to verify that elevated serum HE4 levels correlate with the recurrence of ovarian and endometrial cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|